BLCONYSEOphthalmic GoodsFiscal year ends December 31
Bausch & Lomb Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$16.61+0.12 (+0.73%)
Close on Oct 19, 2026
- Market cap
- $5.93B
- P/E (TTM)
- –
- Dividend yield
- –
Bausch & Lomb Corp revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vision Care | $784.00M | $711.00M | $778.00M | $736.00M | $753.00M | $656.00M | $723.00M | $684.00M | $697.00M | $635.00M | $662.00M | $648.00M | 56.2% | +4.1% |
| Pharmaceuticals | $354.00M | $305.00M | $378.00M | $330.00M | $309.00M | $267.00M | $326.00M | $306.00M | $310.00M | $267.00M | $307.00M | $174.00M | 25.4% | +14.6% |
| Surgical | $256.00M | $228.00M | $249.00M | $215.00M | $216.00M | $214.00M | $231.00M | $206.00M | $209.00M | $197.00M | $204.00M | $185.00M | 18.4% | +18.5% |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vision Care | $229.00M | $202.00M | $247.00M | $217.00M | $209.00M | $176.00M | $237.00M | $201.00M | $192.00M | $178.00M | $186.00M | $182.00M | +9.6% |
| Pharmaceuticals | $89.00M | $66.00M | $134.00M | $76.00M | $37.00M | $11.00M | $56.00M | $69.00M | $78.00M | $53.00M | $74.00M | $53.00M | +140.5% |
| Surgical | $17.00M | $9.00M | $15.00M | $8.00M | $2.00M | -$7.00M | $16.00M | $13.00M | $4.00M | $11.00M | $21.00M | $9.00M | +750.0% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $1.39B | $1.24B | $1.40B | $1.28B | $1.27B | $1.13B | $1.28B | $1.19B | $1.21B | $1.09B | $1.17B | $1.00B | 99.6% | +9.2% |
| Devices | $524.00M | $480.00M | $518.00M | $484.00M | $472.00M | $448.00M | $476.00M | $455.00M | $445.00M | $424.00M | $425.00M | $411.00M | 37.6% | +11.0% |
| OTC | $497.00M | $444.00M | $490.00M | $454.00M | $482.00M | $409.00M | $462.00M | $420.00M | $447.00M | $395.00M | $429.00M | $408.00M | 35.7% | +3.1% |
| Pharmaceuticals | $300.00M | $266.00M | $319.00M | $280.00M | $260.00M | $222.00M | $268.00M | $247.00M | $245.00M | $209.00M | $263.00M | $113.00M | 21.5% | +15.4% |
| Branded and Other Generics | $68.00M | $49.00M | $71.00M | $59.00M | $58.00M | $54.00M | $69.00M | $70.00M | $76.00M | $66.00M | $51.00M | $72.00M | 4.9% | +17.2% |
| Other revenues | $5.00M | $5.00M | $7.00M | $4.00M | $6.00M | $4.00M | $5.00M | $4.00M | $3.00M | $5.00M | $5.00M | $3.00M | 0.4% | -16.7% |
| Other revenues | $5.00M | $5.00M | $7.00M | $4.00M | $6.00M | $4.00M | $5.00M | $4.00M | $3.00M | $5.00M | $5.00M | $3.00M | 0.4% | -16.7% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poland | – | – | – | – | – | – | $15.00M | $17.00M | $18.00M | $15.00M | $14.00M | $11.00M | – | – |
| Japan | – | – | – | – | – | – | $50.00M | $45.00M | $43.00M | $42.00M | $48.00M | $45.00M | – | – |
| France | – | – | – | – | – | – | $51.00M | $52.00M | $64.00M | $60.00M | $45.00M | $47.00M | – | – |
| Germany | – | – | – | – | – | – | $32.00M | $38.00M | $40.00M | $42.00M | $32.00M | $33.00M | – | – |
| Canada | – | – | – | – | – | – | $34.00M | $33.00M | $32.00M | $28.00M | $30.00M | $27.00M | – | – |
| U.S. and Puerto Rico | – | – | – | – | – | – | $657.00M | $609.00M | $610.00M | $537.00M | $593.00M | $471.00M | – | – |
| Italy | – | – | – | – | – | – | $23.00M | $22.00M | $23.00M | $23.00M | $21.00M | $19.00M | – | – |
| South Korea | – | – | – | – | – | – | $12.00M | $12.00M | $11.00M | $12.00M | $11.00M | $12.00M | – | – |
| United Kingdom | – | – | – | – | – | – | $35.00M | $33.00M | $33.00M | $31.00M | $32.00M | $31.00M | – | – |
| Spain | – | – | – | – | – | – | $26.00M | $20.00M | $25.00M | $21.00M | $23.00M | $18.00M | – | – |
| China | – | – | – | – | – | – | $96.00M | $92.00M | $93.00M | $77.00M | $94.00M | $87.00M | – | – |
| Russia | – | – | – | – | – | – | $32.00M | $31.00M | $29.00M | $28.00M | $30.00M | $26.00M | – | – |
| Mexico | – | – | – | – | – | – | $20.00M | $18.00M | $20.00M | $17.00M | $18.00M | $19.00M | – | – |
| Australia | – | – | – | – | – | – | – | – | – | – | – | $11.00M | – | – |
| Other | – | – | – | – | – | – | $197.00M | $174.00M | $175.00M | $166.00M | $182.00M | $161.00M | – | – |
From the segment and revenue-disaggregation notes of Bausch & Lomb's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.